← 產業報告目錄
mRNA Treatment Market Size, Share & Trends Analysis Report By Product Type (Prophylactic vaccines, Therapeutic vaccines, Therapeutic drugs), By Therapeutic Area, By Route of Administration, By Region, And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-14頁數 185報告編號 INSIGHTACE-14aacbc026
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The mRNA Treatment Market is positioned for steady expansion, with a projected CAGR of 9.0% from 2028 to 2034. MRNA Treatment covers key industry insights & findings from the report:
The rising existance of chronic diseases such as cancer, viral infections, and genetic disorders is driving the demand for mrna treatments. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Market momentum is bolstered by rising call for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold marked shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and rising investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global mRNA Treatment Market Snapshot
Chapter 4. Global mRNA Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter's Five Forces Analysis
4.6. Clinical Trial/Pipeline Analysis
4.7. COVID 19 Impact Analysis on Healthcare Industry
Chapter 5. Market Segmentation 1: Product Type Estimates & Trend Analysis
5.1. Product Type & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Product Type:
5.2.1. mRNA Vaccines
5.2.2. mRNA Therapeutic
Chapter 6. Market Segmentation 2: Therapeutic Area Estimates & Trend Analysis
6.1. Therapeutic Area & Market Share, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Therapeutic Area:
6.2.1. Infectious Diseases
6.2.2. Oncological Disorders
6.2.3. Other Disorders
Chapter 7. Market Segmentation 3: Route of Administration Estimates & Trend Analysis
7.1. Route of Administration & Market Share, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Route of Administration:
7.2.1. Intravenous
7.2.2. Intramuscular
7.2.3. Intranasal
7.2.4. Others
Chapter 8. mRNA Treatment Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America mRNA Treatment Market revenue (US$ Million) estimates and forecasts by Product Type, 2024-2031
8.1.2. North America mRNA Treatment Market revenue (US$ Million) estimates and forecasts by Therapeutic Area, 2024-2031
8.1.3. North America mRNA Treatment Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2024-2031
8.1.4. North America mRNA Treatment Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe mRNA Treatment Market revenue (US$ Million) by Product Type, 2024-2031
8.2.2. Europe mRNA Treatment Market revenue (US$ Million) by Therapeutic Area, 2024-2031
8.2.3. Europe mRNA Treatment Market revenue (US$ Million) by Route of Administration, 2024-2031
8.2.4. Europe mRNA Treatment Market revenue (US$ Million) by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific mRNA Treatment Market revenue (US$ Million) by Product Type, 2024-2031
8.3.2. Asia Pacific mRNA Treatment Market revenue (US$ Million) by Therapeutic Area, 2024-2031
8.3.3. Asia Pacific mRNA Treatment Market revenue (US$ Million) by Route of Administration, 2024-2031
8.3.4. Asia Pacific mRNA Treatment Market revenue (US$ Million) by country, 2024-2031
8.4. Latin America
8.4.1. Latin America mRNA Treatment Market revenue (US$ Million) by Product Type, 2024-2031
8.4.2. Latin America mRNA Treatment Market revenue (US$ Million) by Therapeutic Area, 2024-2031
8.4.3. Latin America mRNA Treatment Market revenue (US$ Million) by Route of Administration, 2024-2031
8.4.4. Latin America mRNA Treatment Market revenue (US$ Million) by country, (US$ Million) 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa mRNA Treatment Market revenue (US$ Million) by Product Type, 2024-2031
8.5.2. Middle East & Africa mRNA Treatment Market revenue (US$ Million) by Therapeutic Area, 2024-2031
8.5.3. Middle East & Africa mRNA Treatment Market revenue (US$ Million) by Route of Administration 2024-2031
8.5.4. Middle East & Africa mRNA Treatment Market revenue (US$ Million) by country, (US$ Million) 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. CureVac
9.2.2. Moderna
9.2.3. BioNTech (Pfizer)
9.2.4. Translate Bio(Sanofi)
9.2.5. Ethris (AstraZeneca)
9.2.6. Kernal Biologics
9.2.7. Silence Therapeutics
9.2.8. eTheRNA (Etherna Immunotherapies)
9.2.9. Tiba Biotechnology
9.2.10. In-Cell-Art
9.2.11. Anima Biotech
9.2.12. H3 Biomedicine Inc.
9.2.13. Arcturus Therapeutics
9.2.14. eFFECTOR Therapeutics, Inc.
9.2.15. Ionis Pharmaceuticals, Inc.
9.2.16. Stemirna Therapeutics Co., Ltd.
9.2.17. Skyhawk Therapeutics, Inc.
9.2.18. RNAimmune (Sirnaomics)
9.2.19. Ziphius Therapeutics NV
9.2.20. miRagen Therapeutics, Inc.
9.2.21. GlaxoSmithKline plc
9.2.22. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們